Does Ozempic Lower Testosterone? Male Fertility Evidence

The most common version of this question — “does Ozempic lower testosterone?” — has the relationship backwards for the men most likely to be asking it. In men with obesity, excess fat lowers testosterone (through aromatization of testosterone to estradiol and suppression of the hypothalamic-pituitary-gonadal axis), and losing weight reliably raises it. The Corona 2013 systematic review and meta-analysis^[1] is the cleanest statement of this: body-weight loss reverts obesity-associated hypogonadotropic hypogonadism, with the testosterone gain scaling to the amount of weight lost. GLP-1 receptor agonists (semaglutide — Ozempic, Wegovy; tirzepatide — Zepbound, Mounjaro) produce the largest non-surgical weight loss available — STEP-1 −14.9%^[11], SURMOUNT-1 −20.9%^[12] — so for an obese man, the expected direction is testosterone up, not down. There is no established direct suppressive effect of GLP-1s on the HPG axis in humans. On male fertility the honest answer is narrower: obesity impairs semen quality, weight loss may improve it, and the GLP-1-specific human reproductive data is early and limited — emerging, not alarming. This article separates the well-supported story from the genuinely unknown.

The honest summary

• In men with obesity, GLP-1-driven weight loss usually raises testosterone, not lowers it. Obesity is a leading cause of low testosterone in men. The Corona 2013 meta-analysis^[1] showed body-weight loss reverts obesity-associated hypogonadotropic hypogonadism, with the rise in total testosterone proportional to weight lost.
• There is no established direct GLP-1 effect that suppresses testosterone in humans. No published human trial shows semaglutide or tirzepatide directly lowering the HPG axis. The hormone change men experience is the well-documented weight-loss-raises-testosterone effect, working through fat loss.
• The mechanism is aromatase and the HPG axis. Adipose tissue expresses aromatase, converting testosterone to estradiol; obesity also blunts hypothalamic GnRH pulses. Both lower circulating testosterone in heavier men — and both partly reverse with weight loss (Grossmann 2020^[3], EMAS longitudinal data Camacho 2013^[2]).
• Where the “lowering” fear comes from. Severe, rapid caloric restriction in general can transiently perturb reproductive hormones — but that is the physiology of crash dieting and very low energy availability, not the typical 0.5–1 kg/week outcome of a properly titrated GLP-1.
• Male fertility / sperm: limited but reassuring direction. Higher BMI is associated with worse semen parameters (Sermondade 2013 meta-analysis^[5]); weight loss may improve semen quality in obese subfertile men (Pereira 2025 review^[6]). The GLP-1-specific human reproductive evidence is early (Deameh 2026 systematic review^[7]; Merhi 2026 narrative review^[8]) — no strong human signal that GLP-1s harm sperm, and the topic is explicitly emerging.
• GLP-1 receptor agonists exist in reproductive tissue. GLP-1 receptors have been identified in testis and other reproductive tissue, mostly in animal models. This is a basic-science observation, not human clinical evidence of harm or benefit.
• You can take TRT and Ozempic together. It is commonly done for hypogonadal men with obesity, and there is no known pharmacokinetic interaction. The combination is biologically sensible but not RCT-validated for weight outcomes — see the dedicated stacking article.
• Check the right labs at the right time. Confirm low testosterone with two morning total-T draws plus symptoms before concluding anything (Bhasin 2018^[9]); for fertility concerns, a semen analysis is the test, not a testosterone level.

Why people fear Ozempic lowers testosterone (and why it usually doesn't)

The query “does Ozempic lower testosterone” is popular partly because two true facts get fused into a false one. Fact one: very aggressive caloric restriction and very low energy availability can transiently suppress reproductive hormones — this is well established in extreme dieting, eating disorders, and over-training physiology. Fact two: GLP-1 receptor agonists cause weight loss by reducing food intake. The intuitive leap — “therefore Ozempic starves the body and tanks testosterone” — does not survive contact with the data for the population actually taking these drugs.

For a man with obesity, the dominant hormonal signal of weight loss is the reversal of obesity-associated hypogonadism, which raises testosterone. A correctly titrated GLP-1 produces gradual, sustained weight loss (roughly 0.5–1 kg per week after dose escalation), not the kind of acute starvation physiology that perturbs the HPG axis. The net effect observed across the weight-loss literature in men with obesity is a measurable rise in total — and often free — testosterone, not a fall.

Why obesity lowers testosterone in the first place

Understanding the mechanism is what makes the direction of the GLP-1 effect predictable. Obesity lowers testosterone in men through two converging pathways:

1. Aromatization. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. More fat mass means more peripheral conversion, so a heavier man has lower circulating testosterone and higher estradiol than a leaner peer even when the testes are working normally. That estrogen shift is also one reason heavier men are more prone to true breast-gland growth, as distinct from simple chest fat — see man boobs: chest fat vs. gynecomastia.
2. HPG-axis suppression. Higher estradiol plus adipokine and inflammatory signals (leptin, IL-6, TNF-alpha) blunt hypothalamic GnRH pulse frequency, which lowers pituitary LH, which lowers Leydig-cell testosterone output. The result is the classic “functional” or “hypogonadotropic” hypogonadism of obesity: low testosterone with normal-to-low LH and a structurally normal pituitary.

Both pathways are at least partly reversible. Remove the excess adipose tissue and you remove the excess aromatase and the suppressive adipokine load — which is exactly why weight loss raises testosterone. Grossmann 2020^[3] is the modern review of this obesity-hypogonadism phenotype and its metabolic reversibility.

The evidence: weight loss raises testosterone

Corona 2013 (Eur J Endocrinol)^[1] is the central reference. This systematic review and meta-analysis pooled weight-loss interventions (low-calorie diet and bariatric surgery) in men and asked what happened to testosterone. The finding: body-weight loss reverts obesity-associated hypogonadotropic hypogonadism, and the magnitude of the testosterone increase is proportional to the amount of weight lost. Bariatric surgery (the largest weight loss) produced the largest testosterone gains; diet-induced weight loss produced smaller but still meaningful increases. The estradiol-lowering and SHBG-raising effects were concordant, which raises calculated free testosterone as well.

EMAS longitudinal data (Camacho 2013)^[2] followed several thousand middle-aged and older European men over time. Weight gain accelerated the age-related fall in testosterone; weight loss (greater than ~15% of body weight) blunted or reversed it, with mean total-testosterone increases on the order of 2–3 nmol/L (roughly 60–90 ng/dL) in men who achieved large sustained loss. Estradiol fell and SHBG rose in parallel.

Khoo 2013 (J Sex Med)^[4] adds the exercise angle: obese men randomized to higher-volume moderate-intensity exercise improved both sexual function and total testosterone, with a dose-response, even at relatively modest weight loss. The point for the GLP-1 reader: the testosterone benefit of weight loss is robust across the way the weight is lost — diet, exercise, surgery — so there is no mechanistic reason to expect GLP-1-driven weight loss to behave differently.

Putting it together: a man with obesity who loses 15–20% of body weight on a GLP-1, sustained, has a reasonable expectation that his testosterone moves up, not down — the same direction diet, exercise, and bariatric surgery produce at comparable weight loss.

Does GLP-1 directly suppress the HPG axis? No established human effect

Separate from the weight-loss-driven changes, the narrower scientific question is whether GLP-1 signaling itself does something to the reproductive axis independent of fat loss. As of 2026, there is no established direct suppressive effect of GLP-1 receptor agonists on the human HPG axis. The recent systematic review by Deameh 2026 (J Sex Med)^[7] of GLP-1 effects on male reproductive hormones, semen parameters, and metabolic outcomes found that the available human data point toward neutral-to-favorable hormonal changes (consistent with the weight-loss mechanism), with the literature still thin and heterogeneous. There is no human trial demonstrating that semaglutide or tirzepatide lowers testosterone through a direct receptor effect.

GLP-1 receptors have been identified in reproductive tissue, including the testis, predominantly in animal models. Some preclinical work suggests GLP-1 signaling may even be supportive of certain reproductive functions. But this is basic science — receptor-mapping and animal experiments do not establish a clinical effect in men, in either direction. The honest framing is: a plausible biological substrate exists for a direct effect, but it has not been demonstrated to lower testosterone or harm fertility in humans.

GLP-1 and male fertility / sperm: what is and isn't known

This is the part of the topic where overclaiming is most tempting and least justified. Here is the layered evidence, from best-supported to most uncertain:

Obesity is associated with worse semen quality. Sermondade 2013 (Hum Reprod Update)^[5], an updated systematic review and collaborative meta-analysis, found a relationship between higher BMI and abnormal sperm counts (including oligozoospermia and azoospermia). Obesity is also associated with lower testosterone, higher estradiol, erectile dysfunction, and metabolic disease — all of which can sit alongside reduced fertility.

Weight loss may improve semen quality in obese men. Pereira 2025 (Hum Reprod)^[6] reviewed weight-loss interventions for obesity-related male infertility and described improvements in reproductive hormones and, in some studies, semen parameters with significant weight loss — while emphasizing that the human intervention data are limited and not uniformly positive. The signal direction is favorable, the certainty is modest.

GLP-1-specific human reproductive data is early. The Deameh 2026 systematic review^[7] and the Merhi 2026 narrative review (Sex Med Rev)^[8] both reach the same bottom line: the human evidence on GLP-1 receptor agonists and male reproductive function — including semen parameters — is emerging, small, and heterogeneous, with an explicit call for further research. There is no strong human evidence that GLP-1s harm sperm, and the favorable indirect mechanism (weight loss improves the metabolic milieu) coexists with genuine uncertainty about any direct effect.

Can you take Ozempic and testosterone (TRT) together?

Yes — this is a common and biologically sensible combination for a man who has both obesity and confirmed hypogonadism, and there is no known pharmacokinetic interaction between testosterone and the GLP-1 receptor agonists. Testosterone is a steroid hormone; semaglutide, tirzepatide, and liraglutide are peptide drugs cleared by general proteolysis and renal routes. They do not compete on a shared metabolic pathway.

The clinical logic for the combination: a GLP-1 produces the calorie deficit and the weight loss, while testosterone (in a man with genuinely low testosterone) helps preserve lean mass and shifts body composition toward muscle. Because GLP-1 weight loss carries a documented lean-mass-loss component, the lean-mass-preservation argument is the strongest rationale for combining them in a hypogonadal man. The important caveats are unchanged from any TRT decision: confirm hypogonadism properly first, monitor hematocrit, PSA, and lipids, and remember that exogenous testosterone suppresses spermatogenesis — so for a man who wants to conceive, TRT is the wrong tool and gonadotropin-preserving alternatives should be discussed. The combination is not RCT-validated for weight outcomes; the data are observational and extrapolated. See the dedicated stacking article for the full protocol and monitoring discussion.

When to check labs and see a doctor

• Confirm before concluding. If you suspect low testosterone, the diagnosis requires two morning (before 10 AM) total-testosterone measurements below the lab's reference range plus consistent symptoms, per the Endocrine Society 2018 guideline (Bhasin 2018^[9]). A single afternoon value is not a diagnosis. Harmonized reference ranges (Travison 2017^[10]) put the lower normal limit for healthy young men around 264 ng/dL.
• Re-check after meaningful weight loss. If a baseline testosterone was low and you then lose 10–20% of body weight on a GLP-1, it is reasonable to re-measure — functional hypogonadism from obesity often improves, sometimes enough to avoid exogenous testosterone entirely.
• For fertility questions, order a semen analysis. Testosterone level and fertility are different questions. A man worried about sperm should get a semen analysis (with repeat testing, since semen parameters vary) rather than inferring fertility from a hormone panel.
• See a clinician for new or persistent symptoms. Low libido, erectile dysfunction, fatigue, or loss of morning erections deserve evaluation that includes testosterone, but also screens for the common confounders — sleep apnea, depression, alcohol, medications, and uncontrolled diabetes.
• Planning conception? Discuss GLP-1 timing and any washout with your clinician, and do not start exogenous testosterone if near-term fertility matters.

Compare GLP-1 providers

Many of the telehealth platforms that prescribe GLP-1 receptor agonists also offer testosterone and men's-health services through the same membership, which is convenient but not a substitute for a proper hypogonadism workup. Confirm clinician credentials, the labs drawn before any testosterone prescription, and pharmacy sourcing before committing.

Bottom line

• In men with obesity, GLP-1-driven weight loss typically raises testosterone, because it reverses obesity-associated hypogonadism (Corona 2013^[1], EMAS Camacho 2013^[2], Grossmann 2020^[3]). The popular fear that “Ozempic lowers testosterone” has the direction backwards for this population.
• There is no established direct suppressive effect of GLP-1 receptor agonists on the human HPG axis (Deameh 2026^[7]). GLP-1 receptors exist in reproductive tissue but that is animal/basic-science data, not human evidence of harm.
• Severe crash dieting can transiently disturb reproductive hormones — but a properly titrated GLP-1 produces gradual weight loss, not starvation physiology.
• Male fertility: obesity is linked to worse semen quality (Sermondade 2013^[5]); weight loss may improve it (Pereira 2025^[6]); GLP-1-specific human reproductive data is early and limited (Deameh 2026^[7], Merhi 2026^[8]) — no strong evidence of harm, but emerging, not settled.
• TRT and a GLP-1 can be used together for a man with confirmed hypogonadism and obesity; no pharmacokinetic interaction, biologically sensible, not RCT-validated for weight outcomes. Exogenous testosterone suppresses sperm production — the wrong tool if conception is a near-term goal.
• Confirm low testosterone with two morning draws plus symptoms before acting (Bhasin 2018^[9]); use a semen analysis for fertility questions; discuss GLP-1 timing with a clinician if planning conception.